• Diabetes

Tradjenta Generic Name & Formulations

General Description

Linagliptin 5mg; tabs.

Pharmacological Class

Dipeptidyl peptidase-4 (DPP-4) inhibitor.

How Supplied

Tabs—30, 90

Generic Availability


Tradjenta Indications


Adjunct to diet and exercise in type 2 diabetes mellitus, as monotherapy or combination therapy.

Limitations of Use

Not for treatment of type 1 diabetes. Not studied in patients with a history of pancreatitis.

Tradjenta Dosage and Administration


5mg once daily.


<18yrs: not established.

Tradjenta Contraindications

Not Applicable

Tradjenta Boxed Warnings

Not Applicable

Tradjenta Warnings/Precautions


Consider risks/benefits in patients with known risk factors for heart failure; monitor for signs/symptoms; evaluate and consider discontinuing if develops. Monitor for signs/symptoms of pancreatitis, serious hypersensitivity reactions, severe joint pain, or bullous pemphigoid; discontinue if suspected or occurs. History of angioedema to other DPP-4 inhibitors. Pregnancy. Nursing mothers.

Tradjenta Pharmacokinetics

See Literature

Tradjenta Interactions


Antagonized by strong P-gp or CYP3A4 inducers (eg, rifampin); consider alternatives to linagliptin if used in combination. May need lower doses of the concomitant insulin secretagogue (eg, sulfonylurea) or insulin to reduce risk of hypoglycemia.

Tradjenta Adverse Reactions

Adverse Reactions

Nasopharyngitis, diarrhea, cough, hypoglycemia; hypersensitivity reactions (eg, anaphylaxis, urticaria, angioedema, exfoliative skin conditions, bronchial hyperreactivity), myalgia, pancreatitis, severe and disabling arthralgia, bullous pemphigoid.

Tradjenta Clinical Trials

See Literature

Tradjenta Note

Not Applicable

Tradjenta Patient Counseling

See Literature